Brainsway Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Brainsway Ltd., a foreign private issuer, for the month of June 2026. The report, dated June 29, 2026, and signed by CEO Hadar Levy, primarily serves to incorporate by reference a press release regarding clinical data.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on clinical developments rather than financial performance.
Material Changes and Clinical Developments
The primary material event disclosed is the presentation of positive data from the largest real-world study of Deep TMS in patients with comorbid Post-Traumatic Stress Disorder (PTSD) and Major Depressive Disorder (MDD). This data is detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide specific financial guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the context of the clinical study results.
Investor Verification Checklist
- Review Exhibit 99.1 for the full details of the Deep TMS real-world study results.
- Verify the specific clinical endpoints and statistical significance of the data presented.
- Check subsequent filings for any financial impact or commercialization plans resulting from this study.
- Confirm the regulatory status of Deep TMS for the specific comorbid indications mentioned.